On March 2, 2018, the manufacturers of Zinbryta (daclizumab) – a drug used in the treatment of some forms of multiple sclerosis – announced that they would stop making the drug because of concerns about serious side effects.
The changes in this bulletin apply to all groups that use the PAI Preferred Drug List.
PAI is excited to introduce a new Preferred Blue provider (PPO) network logo.
The changes in this bulletin go into effect July 1, 2018, unless noted otherwise. They apply to PAI groups that use the Caremark Preferred Drug List.
The Pharmacy & Therapeutics (P&T) Committee has worked diligently to develop an Opioid Management Program slated to begin April 1, 2018.
Bardavon Health Innovations and Planned Administrators, Inc. to Launch Integrated Commercial Health and Workers’ Compensation Solution